Skip to main content
Premium Trial:

Request an Annual Quote

N-of-One to Analyze NGS Tests of Patients at Dartmouth-Hitchcock Norris Cotton Cancer Center

NEW YORK (GenomeWeb News) – N-of-One announced today a deal to provide clinical interpretation of next-generation sequencing tests run at the Dartmouth-Hitchcock Medical Center as part of the Norris Cotton Cancer Center's comprehensive molecular diagnostics and treatment program.

Lexington, Mass.-based N-of-One will analyze NGS test results for each Dartmouth-Hitchcock patient's cancer and deliver clinical interpretation as part of the deal. The company's analysis links biological and clinical knowledge, as well as insights into the mutation profile for each tumor, with therapeutic strategies, including clinical trials, enabling Dartmouth-Hitchcock physicians to make more molecularly based personalized treatment decisions, N-of-One said.

Financial and other terms of the agreement were not disclosed.

"With the costs for gene sequencing technology decreasing, the knowledge about molecularly guided therapies and the resulting complexity of interpreting the data is exploding," N-of-One CEO Chris Cournoyer said in a statement. "We are helping leading cancer centers implement comprehensive genomic sequencing by providing the link to the knowledge of therapeutic options in a scalable, cost-effective way."

The deal follows last week's announcement by N-of-One and Syapse of a partnership to combine their products into an integrated informatics solution for clinical data interpretation.